OGT Services, WTCHG Develop In Situ Customized Arrays
OGT Services, a unit of Oxford Gene Technology, and researchers at the Wellcome Trust Center for Human Genomics at the University of Oxford have developed a method for in situ spotting of double-stranded DNA microarrays, OGT said last week.
According to Ioannis Ragoussis, head of genomics at WTCHG, the center decided to pair off with OGT Services in order "to establish binding profiles of human transcription factors using their in-house microarray system."
"The sequences in question are particularly long so we knew we would need a customised system," he said. WTCHG is one of OGT Services newer clients.
According to Mike Evans, OGT's CEO designate, the custom array service has been developing its market over the past 12 to 18 months, and is part of a larger strategy to expand OGT's business from licensing to more straight forward commercial ventures.
"We are developing a services-based business, which is designing arrays for people, and taking them through the initial design of the array for a customer, through using the array, to interpreting the data from the array as well," he told BioArray News last month.
"There [are] a lot of different applications for bioarrays, and we feel that there's a need in the marketplace for a very flexible and responsive service for customers."
OSU, BioImagene Partner for Cancer Research and Drug Discovery
BioImagene and Ohio State University's College of Medicine have entered into a collaborative agreement to work together on research projects and projects with the potential for profit, the two parties announced last week.
According to Mohan Uttarwar, BioImagene's CEO and president, the deal will provide his company with access "to a vast number of tissue samples, clinical data, outcome data, and deep domain knowledge with the experts to validate [their] results." The company uses its imaging technology to aid in cancer research and biomarker discovery.
Sanford Barsky, chair of OSU's department of pathology, said that the agreement will permit the two parties "to develop and validate imaging algorithms that can be applied to various areas of anatomical pathology, including tissue microarray interpretation, immunocytochemistry, in situ hybridization, and hematoxylin and eosin-based diagnosis."
Financial details were not discussed.
Health Discovery Acquires SVM Patent Portfolio, Launches Licensing Business
Health Discovery has completed its acquisition of the patent portfolio support vector machines, bioinformatics tools that are useful for gene and protein expression analysis, and has launched a licensing and development offering, the company said this week.
The portfolio was acquired from private researchers, including Vladimir Vapnik and Isabelle Guyon, co-inventors of SVM, now members of HDVY's Scientific Team.
The company is now in a position to offer exclusive licenses of these patents in many fields including biomarker discovery. According to the Savannah, GA.-based firm their target market for licensing and development includes educational and research institutions that can use SVMs for classifying gene and protein array expression data.
BioArray Solutions to Launch BeadChip Test in Q4
BioArray Solutions will launch its HEA BeadChip Test by the end of the year, a spokesperson told BioArray News this week.
Donna DeLong, part of the Warren, New Jersey-based company's marketing and business development team, said that the firm is beta-testing the chip, and expects it to be commercially available for researchers by the fourth quarter.
Michael Seul, president of BioArray Solutions, in a statement said the BeadChip test, a high-throughput genotyping assay with probes targeting 17 mutations in various blood group systems, will be useful in determining "the DNA type of large numbers of donors at the rate of throughput required in transfusion medicine."
In addition to beta-testing the chip, BioArray Solutions also paired with investigators from the New York Blood Center to compare the technology to competitive technologies, such as serological hemagglutination. The results are published in this month's issue of Transfusion, the journal of the American Association of Blood Banks.
Marion Reid, director of NYBC's Immunohematology Lab said that the BeadChip test "would be especially useful for chronically transfused patients to reduce and ideally prevent the incidence of alloimmunization to blood group antigens."